文献速递神经肿瘤

高级别脑膜瘤中的BAP1突变:对患者管理的意义

BAP1 mutations in high-grade meningioma: implications for patient care.
PubMed 文献 · Neuro Oncol · 2017-01-01

本文综述了BAP1肿瘤抑制基因在部分侵袭性横纹肌样脑膜瘤中失活的研究发现。BAP1蛋白免疫组化可快速筛查疑似病例,部分BAP1突变脑膜瘤患者携带胚系BAP1突变及BAP1肿瘤易感综合征。作者建议神经病理学家评估肿瘤BAP1状态并仔细采集家族史,在适当临床情境下进行遗传咨询和胚系BAP1 DNA测序。

要点

  • BAP1蛋白免疫组化是筛查疑似横纹肌样脑膜瘤的快速 inexpensive 方法
  • 部分BAP1突变脑膜瘤患者携带胚系BAP1突变及BAP1肿瘤易感综合征
  • 几乎所有胚系BAP1突变携带者至55岁时发生恶性肿瘤

核心结论

  • BAP1在部分临床侵袭性横纹肌样脑膜瘤中失活,BAP1蛋白免疫组化可用于快速筛查疑似病例。
  • 部分BAP1突变脑膜瘤患者携带胚系BAP1突变及BAP1肿瘤易感综合征。
  • 面对潜在高级别横纹肌样脑膜瘤患者,神经病理学家应评估肿瘤BAP1状态并仔细采集癌症家族史。
  • 在适当临床情境下,应进行遗传咨询和胚系BAP1 DNA测序。
  • 针对胚系BAP1突变携带者的癌症监测项目可能有助于在早期可治疗阶段发现葡萄膜黑色素瘤、皮肤黑色素瘤和肾细胞癌。

研究设计与样本

  • 本文为综述,总结作者近期关于BAP1肿瘤抑制基因在部分侵袭性横纹肌样脑膜瘤中失活的研究发现。

主要发现

  • BAP1肿瘤抑制基因在部分显示横纹肌样组织形态的临床侵袭性脑膜瘤中失活。
  • BAP1蛋白免疫组化提供了一种快速且 inexpensive 的疑似病例筛查方法。
  • 部分BAP1突变脑膜瘤患者携带胚系BAP1突变及BAP1肿瘤易感综合征。
  • 似乎几乎所有胚系BAP1突变患者至55岁时发生恶性肿瘤,最常见为葡萄膜黑色素瘤、皮肤黑色素瘤、胸膜或腹膜恶性间皮瘤或肾细胞癌,其他癌症也与BAP1肿瘤易感综合征相关。
  • BAP1突变脑膜瘤为罕见肿瘤,需多机构合作评估治疗策略并进一步明确其临床病理特征。

临床怎么用

  • 神经病理学家应评估潜在高级别横纹肌样脑膜瘤的BAP1状态,并仔细采集患者癌症家族史。
  • 在适当临床情境下,应进行遗传咨询和胚系BAP1 DNA测序。
  • 针对胚系BAP1突变携带者的癌症监测项目可能有助于在早期可治疗阶段发现葡萄膜黑色素瘤、皮肤黑色素瘤和肾细胞癌。
  • BAP1突变脑膜瘤罕见,需多机构合作评估治疗策略并进一步明确临床病理特征。

局限性

  • BAP1突变脑膜瘤为罕见肿瘤,需多机构合作评估治疗策略并进一步明确其临床病理特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We have recently shown that the breast cancer (BRCA)1-associated protein-1 tumor suppressor gene (BAP1) is inactivated in a subset of clinically aggressive meningiomas that display rhabdoid histomorphology. Immunohistochemistry for BAP1 protein provides a rapid and inexpensive method for screening suspected cases. Notably, some patients with BAP1-mutant meningiomas have germline BAP1 mutations and BAP1 tumor predisposition syndrome (TPDS). It appears that nearly all patients with germline BAP1 mutations develop malignancies by age 55, most frequently uveal melanoma, cutaneous melanoma, pleural or peritoneal malignant mesothelioma, or renal cell carcinoma, although other cancers have also been associated with BAP1 TPDS. Therefore, when confronted with a patient with a potentially high-grade rhabdoid meningioma, it is important that neuropathologists assess the BAP1 status of the tumor and that the patient's family history of cancer is carefully ascertained. In the appropriate clinical setting, genetic counseling and germline BAP1 DNA sequencing should be performed. A cancer surveillance program for individuals who carry germline BAP1 mutations may help identify tumors such as uveal melanoma, cutaneous melanoma, and renal cell carcinoma at early and treatable stages. Because BAP1-mutant meningiomas are rare tumors, multi-institutional efforts will be needed to evaluate therapeutic strategies and to further define the clinicopathologic features of these tumors.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Shankar GM, Santagata S. BAP1 mutations in high-grade meningioma: implications for patient care. Neuro Oncol. 2017. PMID: 28482042. doi:10.1093/neuonc/nox094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。